IL298375A - pcsk9 inhibitors and methods of using them for the treatment of cholesterol-related disorders - Google Patents

pcsk9 inhibitors and methods of using them for the treatment of cholesterol-related disorders

Info

Publication number
IL298375A
IL298375A IL298375A IL29837522A IL298375A IL 298375 A IL298375 A IL 298375A IL 298375 A IL298375 A IL 298375A IL 29837522 A IL29837522 A IL 29837522A IL 298375 A IL298375 A IL 298375A
Authority
IL
Israel
Prior art keywords
ldl
subject
pcsk9
hefh
inhibitor
Prior art date
Application number
IL298375A
Other languages
English (en)
Hebrew (he)
Inventor
Andrew W Hamer
Ian Matthew Bridges
Huei Wang
Andrea Ruzza
Christopher Kurtz
Original Assignee
Amgen Inc
Andrew W Hamer
Ian Matthew Bridges
Huei Wang
Andrea Ruzza
Christopher Kurtz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Andrew W Hamer, Ian Matthew Bridges, Huei Wang, Andrea Ruzza, Christopher Kurtz filed Critical Amgen Inc
Publication of IL298375A publication Critical patent/IL298375A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL298375A 2020-05-29 2021-05-27 pcsk9 inhibitors and methods of using them for the treatment of cholesterol-related disorders IL298375A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063032451P 2020-05-29 2020-05-29
PCT/US2021/034489 WO2021243002A1 (en) 2020-05-29 2021-05-27 Pcsk9 inhibitors and methods of use thereof to treat cholesterol-related disorders

Publications (1)

Publication Number Publication Date
IL298375A true IL298375A (en) 2023-01-01

Family

ID=78722769

Family Applications (1)

Application Number Title Priority Date Filing Date
IL298375A IL298375A (en) 2020-05-29 2021-05-27 pcsk9 inhibitors and methods of using them for the treatment of cholesterol-related disorders

Country Status (11)

Country Link
US (1) US20230235085A1 (https=)
EP (1) EP4157887A4 (https=)
JP (1) JP2023527542A (https=)
CN (1) CN115916838A (https=)
AR (1) AR122180A1 (https=)
AU (1) AU2021281256A1 (https=)
CA (1) CA3179316A1 (https=)
IL (1) IL298375A (https=)
JO (1) JOP20220322A1 (https=)
TW (1) TW202210524A (https=)
WO (1) WO2021243002A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
BR112021013807A2 (pt) 2019-01-18 2021-11-30 Astrazeneca Ab Inibidores de pcsk9 e seus métodos de uso
MX2021008661A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.
AU2024324802A1 (en) 2023-08-14 2026-03-05 Salubris (Chengdu) Biotech Co., Ltd. Method for treating or preventing cholesterol-related diseases using pcsk9 inhibitor
WO2025265012A1 (en) * 2024-06-21 2025-12-26 Amgen Inc. Compositions comprising anti-pcsk9 antbodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2527369A3 (en) * 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
EP2706070A1 (en) * 2012-09-06 2014-03-12 Sanofi Combination treatments involving antibodies to human PCSK9
KR20230074283A (ko) * 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법

Also Published As

Publication number Publication date
CA3179316A1 (en) 2021-12-02
JOP20220322A1 (ar) 2022-11-27
CN115916838A (zh) 2023-04-04
US20230235085A1 (en) 2023-07-27
EP4157887A1 (en) 2023-04-05
EP4157887A4 (en) 2024-07-03
TW202210524A (zh) 2022-03-16
WO2021243002A1 (en) 2021-12-02
AR122180A1 (es) 2022-08-24
AU2021281256A1 (en) 2022-12-22
JP2023527542A (ja) 2023-06-29

Similar Documents

Publication Publication Date Title
US20250051457A1 (en) Asgr inhibitors
US20230235085A1 (en) Pcsk9 inhibitors and methods of use thereof to treat cholesterol-related disorders
JP6060212B2 (ja) Ｐｃｓｋ９拮抗薬
EP2074149B1 (en) Compositions and methods relating to glucagon receptor antibodies
JP7558949B2 (ja) 抗ｃｔｌａ－４結合タンパク質およびその使用方法
JP2022516073A (ja) 抗ｐｄ－１結合タンパク質およびその使用方法
JP7847090B2 (ja) 操作されたｂ型肝炎ウイルス中和抗体およびその使用
JP7783840B2 (ja) 抗ｃｔｌａ－４結合タンパク質及びその使用方法
WO2021253002A1 (en) Recombinant polyclonal proteins targeting covid-19 and methods of use thereof
WO2020142626A1 (en) Anti-ox40 binding proteins and methods of use thereof
CA2779683A1 (en) Anti-c-mpl antibodies
HK40090853A (zh) Pcsk9抑制剂及其用於治疗胆固醇相关障碍的方法
TW202323300A (zh) 抗tigit構築體及其用途
WO2026013632A1 (en) Anti-nectin-4 antibodies and uses thereof